Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

144.95 -1.05 (-0.72%)
Streaming Delayed Price Updated: 9:52 AM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
2 Recession-Resistant Dividend Stocks to Buy Now ↗
It's important to always be prepared. 
Via The Motley Fool
Topics Economy
News headline image
What 16 Analyst Ratings Have To Say About Gilead Sciences ↗
 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD): A Durable Dividend Stock for Income Investors ↗
Via Chartmill
News headline image
3 Blue-Chip Stocks Built for a Rotating Market ↗
Via MarketBeat
News headline image
These 3 Cash Flow Machines Provide Stability in Uncertain Markets ↗
Via MarketBeat
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
Compugen (CGEN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗
Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗
Arcellx shares have jumped 75% in 2026, but that's because the stock will soon be off the market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
P/E Ratio Insights for Gilead Sciences ↗
 
Via Benzinga
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
Kymera (KYMR) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir... 
Via MarketMinute
Topics Intellectual Property
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
Arcus (RCUS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
The global landscape of HIV prevention and treatment has reached a historic turning point following the clinical triumph and subsequent commercial launch of Gilead Sciences’ (Nasdaq: GILD) lenacapavir,... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗
Arcellx shares rose slightly after Gilead Sciences agreed to acquire the company for $7.8 billion, or $115 per share in cash. 
Via Benzinga
News headline image
Is Amgen Stock Outperforming the Dow?
Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects. 
Via Barchart.com
Topics Stocks
News headline image
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal ↗
Gilead Sciences is buying Arcellx for $7.8 billion because it sees potential for more than $6 billion in sales for anito-cel by 2029. GILD stock slipped as ACLX soared. 
Via Investor's Business Daily
News headline image
Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug ↗
Gilead Sciences to acquire Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy for cancer. 
Via Benzinga
News headline image
Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗
Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal. 
Via Stocktwits
News headline image
Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel
From Arcellx, Inc.
Via Business Wire
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
72 73 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.